Does the type of BCR/ABL junction predict the survival of patients with Ph1-positive chronic myeloid leukemia?
The prognostic value of the site of DNA rearrangement within the M-BCR on chromosome 22 or of the type of transcript has been debated in the last years. The majority of the studies do not support the hypothesis of a predictive value of such molecular parameters. Results coming from a multicentric, prospective trial, based on alpha-IFN therapy, seem to indicate a better karyotypic response in 3' rearranged patients. The possibility of evoking a cytotoxic immune response directed towards peptides originating from each of the different BCR/ABL junctions constitute an important challenge for the future.
Zaccaria
A
A
Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia Lorenzo e Ariosto Seràgnoli, Università degli Studi, Bologna, Italia.
Martinelli
G
G
Testoni
N
N
Zuffa
E
E
Farabegoli
P
P
Russo
D
D
Guerrasio
A
A
Tura
S
S
D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D016313:Genes, abl; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology / Q000235:genetics*; D011379:Prognosis; D016019:Survival Analysis
D016044:Fusion Proteins, bcr-abl